

Information on an incidental breach of an obligation resulting from the postponement of the publication of the annual report for 2021. MEDAPP Spółka Akcyjna (PLYLWHT00012)

Current report no. 7/2022 | 17-03-2022 | ESPI

RB_ASO: Report on a request filed with the Polish Financial Supervision Authority for temporary suspension of the proceedings concerning the approval of the Prospectus

The Management Board of MedApp S.A. based in Kraków informs that today, i.e. March 17, 2022. the Company filed with the Office of the Financial Supervision Authority a request for suspension of the proceedings for approval of the Prospectus initiated on July 20, 2020, drawn up in connection with: i the public sale of not fewer than 4,300,000 and not more than 9,400,000 series D shares and not fewer than 3,290,000 and not more than 6,429,642 series E shares; ii the public subscription of not fewer than 1 and not more than 29,000,000 series H shares; and iii the company's application for admission and introduction to trading on a regulated market operated by the WSE of up to 276,160,943 shares with a par value of PLN 0.10 each.

The Company's request for a temporary suspension of the proceedings concerning the approval of the Prospectus is motivated by the current political and economic situation, the related unstable market environment and the uncertainty and volatility of the financial markets. The Company monitors on an ongoing basis the development of the situation and its impact on the market environment and the Company's operations, as well as analyzes the potential risks to the IPO and the transfer of the Company's shares, so far listed in the alternative trading system on the NewConnect market. The Company is considering filing an application for resuming the proceedings once current market conditions have stabilized.

- Krzysztof Mędrala - President of the Management Board

[Link.](#)